Study guide
2.7 Substance Use, Intoxication, and Withdrawal Assessment
ANCC Psychiatric-Mental Health Nurse Practitioner PMHNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Foundation
1.1 Neuroanatomy and Brain Function 1.2 Neurotransmitters and Synaptic Transmission 1.3 Neurodevelopmental and Neuroendocrine Mechanisms 1.4 Psychbehavioral Genetics and Epigenetics 1.5 Psychoneuroimmunology and Inflammatory Pathways 1.6 Psychopathology and Diagnostic Foundations 1.7 Evidence-Based Practice and Research Methodologies 1.8 Lifespan Growth and Development Theories 1.9 Health Promotion and Disease Prevention
2 Chapter 2: Advanced Practice Skills
2.1 Comprehensive Psychiatric Interview and Health History 2.2 Mental Status Examination (MSE) Concepts and Clinical Application 2.3 Physical and Neurological Assessment in Psychiatry 2.4 Diagnostic Laboratory and Imaging Interpretation 2.5 Suicide Risk Assessment and Safety Formulation 2.6 Violence and Homicide Risk Assessment 2.7 Substance Use, Intoxication, and Withdrawal Assessment 2.8 Cultural Competence and Social Determinants of Mental Health 2.9 Therapeutic Alliance and Clinical Communication 2.10 Functional and Diagnostic Risk Stratification
3 Chapter 3: Diagnosis and Treatment
3.1 Neurodevelopmental and Schizophrenia Spectrum Disorders 3.2 Bipolar and Related Disorders 3.3 Depressive Disorders 3.4 Anxiety Disorders, OCD, and Trauma-Related Disorders 3.5 Substance-Related and Addictive Disorders 3.6 Neurocognitive Disorders 3.7 Personality Disorders 3.8 Feeding/Eating, Sleep-Wake, and Somatic Symptom Disorders 3.9 Psychopharmacology Foundations: Antipsychotics and Mood Stabilizers 3.10 Psychopharmacology Foundations: Antidepressants, Anxiolytics, and Stimulants
4 Chapter 4: Psychotherapy and Related Theories
4.1 Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT) 4.2 Psychodynamic and Psychoanalytic Theories 4.3 Humanistic, Person-Centered, and Motivational Interviewing 4.4 Family and Group Psychotherapy Modalities 4.5 Integrative and Complementary Mental Health Approaches
5 Chapter 5: Ethics, Legal Principles, and Cultural Care
5.1 Patient Autonomy, Informed Consent, and Capacity 5.2 Involuntary Commitment and Patient Rights 5.3 Confidentiality, HIPAA, and Duty to Protect 5.4 Professional Scope of Practice and Prescriptive Authority 5.5 Malpractice, Liability, and Risk Management 5.6 Health Policy, Advocacy, and Mental Health Parity 5.7 Quality Improvement, Patient Safety, and Interprofessional Collaboration 5.8 Telepsychiatry, Technology, and Ethical Care Delivery
2.7 Substance Use, Intoxication, and Withdrawal Assessment
Key Takeaways Explain This Topic AI
The CIWA-Ar protocol evaluates alcohol withdrawal across 10 items (max score 67); scores >15 indicate severe withdrawal requiring immediate symptom-triggered benzodiazepines.
The Clinical Opiate Withdrawal Scale (COWS) scores 5-12 (mild), 13-24 (moderate), 25-36 (moderately severe), >36 (severe); buprenorphine induction requires COWS score >=8-12 to prevent precipitated withdrawal.
The CAGE questionnaire screens for alcohol use disorder; a score >=2 indicates 93% sensitivity and 86% specificity for AUD.
The AUDIT screening tool score >=8 for men or >=4 for women indicates hazardous/harmful alcohol consumption requiring clinical intervention.
Last updated: July 2026
Substance Use, Intoxication, and Withdrawal Assessment
Accurate assessment of substance use, intoxication, and withdrawal is a vital skill for the PMHNP. Failure to identify severe withdrawal can lead to life-threatening complications, such as delirium tremens or status epilepticus in alcohol withdrawal. Standardized screening and assessment tools provide objective measures to guide treatment decisions.
SBIRT Framework
The PMHNP should be familiar with the Screening, Brief Intervention, and Referral to Treatment (SBIRT) model, a comprehensive, integrated approach to identifying and treating substance use disorders:
Screening: Universal screening with validated tools (CAGE, AUDIT, DAST-10) at every clinical encounter.
Brief Intervention: A short motivational interviewing conversation (5-15 minutes) to raise awareness and encourage behavioral change.
Referral to Treatment: Connecting patients with moderate-to-severe SUDs to specialty addiction treatment.
Screening Tools for Substance Use
Several validated screening tools are used to identify potential substance use disorders in primary care and psychiatric settings.
1. CAGE Questionnaire: A classic, brief 4-question screen specifically for alcohol use. A score of 2 or more "Yes" answers indicates a high likelihood of alcohol use disorder.
C : Have you ever felt you should C ut down on your drinking?
A : Have people A nnoyed you by criticizing your drinking?
G : Have you ever felt bad or G uilty about your drinking?
E : E ye-opener: Have you ever had a drink first thing in the morning to steady your nerves or to get rid of a hangover?
2. AUDIT (Alcohol Use Disorders Identification Test): Developed by the WHO, this 10-item questionnaire is more comprehensive than the CAGE and assesses alcohol consumption, drinking behaviors, and alcohol-related problems. A score of 8 or more suggests harmful drinking.
3. DAST-10 (Drug Abuse Screening Test): A 10-item self-report scale focusing on drugs other than alcohol. It provides a quick index of drug-related problems. A score greater than 0 suggests further assessment is warranted.
Assessing Alcohol Withdrawal: The CIWA-Ar
The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) is an objective, 10-item scale used to quantify the severity of alcohol withdrawal syndrome and guide symptom-triggered dosing of benzodiazepines.
Components Evaluated (Scored 0-7, except orientation 0-4):
- Nausea and vomiting
- Tremor (arms extended and fingers spread apart)
- Paroxysmal sweats
- Anxiety
- Agitation
- Tactile disturbances
- Auditory disturbances
- Visual disturbances
- Headache, fullness in head
- Orientation and clouding of sensorium
Scoring Interpretation:
0-8: Mild withdrawal. Usually managed with supportive care; medication may not be necessary.
9-15: Moderate withdrawal. Often requires medication (e.g., chlordiazepoxide, lorazepam).
>15: Severe withdrawal. High risk for seizures and delirium tremens (DTs). Requires immediate pharmacological intervention and close monitoring.
Alcohol Withdrawal Timeline and Complications
- Time Since Last Drink Symptoms Clinical Concern
- 6-12 hours Tremor, anxiety, insomnia, nausea Minor withdrawal
- 12-24 hours Alcoholic hallucinosis (clear sensorium) Hallucinations without delirium
- 24-48 hours Generalized tonic-clonic seizures Withdrawal seizures
- 48-96 hours Delirium tremens (DTs) Hyperthermia, autonomic instability, mortality 5% untreated
Clinical Pearl: DTs typically peak at 72 hours and require ICU-level monitoring. Benzodiazepines (lorazepam preferred in hepatic impairment) are first-line. Phenobarbital is second-line.
Assessing Opioid Withdrawal: The COWS
The Clinical Opiate Withdrawal Scale (COWS) is an 11-item clinician-administered tool used to assess opioid withdrawal severity. It is crucial for determining the appropriate time to initiate buprenorphine induction (to avoid precipitated withdrawal).
Components Evaluated:
- Resting pulse rate
- Sweating
- Restlessness
- Pupil size (dilated in withdrawal)
- Bone or joint aches
- Runny nose or tearing (rhinorrhea/lacrimation)
- GI upset (cramps, nausea, vomiting, diarrhea)
- Tremor
- Yawning
- Anxiety or irritability
- Gooseflesh skin (piloerection)
Scoring Interpretation:
- 5-12: Mild
- 13-24: Moderate (Typically the threshold for initiating buprenorphine)
- 25-36: Moderately severe
- >36: Severe
- Buprenorphine Induction Trap: Precipitated Withdrawal
A critical ANCC exam concept: buprenorphine must not be initiated too early . Because buprenorphine is a partial opioid agonist with high receptor affinity, administering it while full agonists (e.g., heroin, oxycodone) still occupy receptors will displace them and precipitate acute withdrawal. The PMHNP must wait until the patient is in moderate withdrawal (COWS >=8-13) before administering the first dose.
Toxicology Screening
Urine Drug Screens (UDS) are a common component of psychiatric assessments, particularly in acute settings or when monitoring adherence to controlled substance prescriptions. However, PMHNPs must understand the limitations and potential for cross-reactivity.
Detection Windows (Approximate):
- Alcohol: 10-12 hours (longer for ethyl glucuronide [EtG] metabolites, up to 3-5 days)
- Amphetamines: 1-3 days
- Benzodiazepines: 1-7 days (longer for long-acting agents like diazepam, up to 30 days)
- Cannabis: 1-3 days for occasional use; up to 30+ days for chronic heavy use
- Cocaine: 1-3 days (metabolite benzoylecgonine)
- Opioids (Heroin/Morphine): 1-3 days
Common False Positives:
Amphetamines: Bupropion, pseudoephedrine, trazodone, selegiline, labetalol.
PCP: Venlafaxine, dextromethorphan, diphenhydramine, ketamine.
Opioids: Poppy seeds, dextromethorphan, fluoroquinolones (rarely).
Benzodiazepines: Sertraline (rarely).
Clinical Pearl: A standard opiate screen tests for natural opiates (morphine, codeine) and heroin (via metabolite). It often misses semi-synthetic or synthetic opioids like oxycodone, fentanyl, buprenorphine, and methadone. Specific assays must be ordered for these substances.
Differentiating Intoxication vs Withdrawal Across Substance Classes
- Substance Intoxication Signs Withdrawal Signs
- Alcohol Disinhibition, ataxia, slurred speech, blackouts Tremor, anxiety, seizures, DTs, hallucinosis
Opioids Miosis, respiratory depression, euphoria, constipation Piloerection, mydriasis, yawning, cramps, rhinorrhea
Stimulants (cocaine/meth) Mydriasis, tachycardia, paranoia, hypertension Hypersomnia, depression, increased appetite, anhedonia
Benzodiazepines Sedation, ataxia, anxiolysis Rebound anxiety, seizures, insomnia, autonomic hyperactivity
Cannabis Euphoria, conjunctival injection, increased appetite Irritability, insomnia, decreased appetite (usually mild)
ANCC Exam Tip: Stimulant withdrawal is predominantly psychological (depression, anhedonia, hypersomnia) and is NOT life-threatening, unlike alcohol or benzodiazepine withdrawal.